• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Most Don't Need 'Bridging' When They Stop Warfarin Temporarily
In this study, Ortel's team randomly assigned patients to take either heparin or an inactive placebo during that time window.In the end, heparin showed no effect on blood-clot risk. Just 0.3 percent of treated patients developed a clot within a month of their procedure, versus 0.4 percent of patients given the placebo, the study found.On the other hand, heparin did boost the odds of serious bleeding. Just over 3 percent of patients developed "major" bleeding, compared with just over 1 percent of placebo patients, the study found.The findings suggest that bridging is unnecessary for most atrial fibrillation patients, Ortel ...
Source: Medical Hemostat - August 26, 2015 Category: Medical Equipment Authors: hemostatguy at gmail.com (hemostat guy) Source Type: blogs

Most Don ' t Need ' Bridging ' When They Stop Warfarin Temporarily
In this study, Ortel ' s team randomly assigned patients to take either heparin or an inactive placebo during that time window. In the end, heparin showed no effect on blood-clot risk. Just 0.3 percent of treated patients developed a clot within a month of their procedure, versus 0.4 percent of patients given the placebo, the study found. On the other hand, heparin did boost the odds of serious bleeding. Just over 3 percent of patients developed " major " bleeding, compared with just over 1 percent of placebo patients, the study found. The findings suggest that bridging is unnecessary for most atrial fibrillation ...
Source: Medical Hemostat - August 26, 2015 Category: Medical Equipment Authors: hemostatguy at gmail.com (hemostat guy) Source Type: blogs

Popular Blood-thinner Manufacturer Didn’t Want Internal Research Made Public
Boehringer Ingelheim, the manufacturer of the blood-thinning drug Pradaxa, was concerned that releasing the results of an internal research paper on the drug would damage drug sales, records recently made public show. The company was so worried about the results of the study that some employees pressured the author to revise it, and the company recommended it be thrown out, according to a recent report by the New York Times.Records recently made public by a federal judge in Illinois presiding over thousands of lawsuits against the maker of Pradaxa, including emails, internal memos, and presentations, centered on the resear...
Source: Medical Hemostat - February 7, 2014 Category: Technology Consultants Authors: hemostatguy at gmail.com (hemostat guy) Source Type: blogs